Beaphar Worming Syrup, 9.4% w/v, Oral Solution

Country: United Kingdom

Language: English

Source: VMD (Veterinary Medicines Directorate)

Active ingredient:

Piperazine Citrate

Available from:

Beaphar UK Ltd

ATC code:

QP52AH01

INN (International Name):

Piperazine Citrate

Pharmaceutical form:

Oral solution

Prescription type:

AVM-GSL - Authorised Veterinary Medicine – General Sales List

Therapeutic group:

Cats, Dogs

Therapeutic area:

Anthelmintic

Authorization status:

Authorized

Authorization date:

1994-09-21

Summary of Product characteristics

Revised: March 2022
AN: 02497/2021
Page 1 of 5
SUMMARY OF PRODUCT CHARACTERISTICS
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Beaphar Worming Syrup, 9.4% w/v, oral solution.
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Active substance
% w/v
Piperazine Citrate
9.4
Excipients
Methyl Parahydroxybenzoate
0.040% w/v
Ethyl Parahydroxybenzoate
0.010% w/v
Propyl Parahydroxybenzoate
0.005% w/v
Butyl Parahydroxybenzoate
0.015% w/v
For full list of excipients, see section 6.1
3.
PHARMACEUTICAL FORM
Oral solution.
Bright reddish brown, clear solution.
4.
CLINICAL PARTICULARS
4.1
TARGET SPECIES
Dogs and cats.
4.2
INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
For the treatment of roundworms (Ascarids) in puppies and kittens.
4.3
CONTRA-INDICATIONS
Do not exceed stated dose.
Do not repeat treatment if vomiting occurs shortly after dosing.
4.4
SPECIAL WARNINGS FOR EACH TARGET SPECIES
Consult a veterinary surgeon before treating pregnant animals, or
those with a history
of epilepsy or severe renal disfunction.
Revised: March 2022
AN: 02497/2021
Page 2 of 5
4.5
SPECIAL PRECAUTIONS FOR USE
i.
Special precautions for use in animals
Do not exceed the recommended dosage.
ii.
Special precautions to be taken by the person administering the
medicinal
product to animals
Following accidental skin or eye contact, wash the affected area with
plenty of
water. If irritation persists, seek medical advice.
Following accidental ingestion, drink plenty of water and seek medical
attention.
Wash hands after use.
4.6
ADVERSE REACTIONS (FREQUENCY AND SERIOUSNESS)
During post-marketing surveillance, transient gastrointestinal signs
(emesis and
diarrhoea) have been observed very rarely.
The frequency of adverse reactions is defined using the following
convention:
- very common (more than 1 in 10 animals treated displaying adverse
reaction(s))
- common (more than 1 but less than 10 animals in 100 animals treated)
- uncommon (more than 1 but less than 10 animals in 1,000 animals
treated)
- rare (more than 1 but less than 10 animals in 10,000 animals